Search

Your search keyword '"Behera Digamber"' showing total 201 results
Start Over Author "Behera Digamber"
201 results on '"Behera Digamber"'

1. Tuberculosis associated immune reconstitution inflammatory syndrome in patients infected with HIV: meningitis a potentially life threatening manifestation

Author

Agarwal Upasna, Kumar Amitabh, Behera Digamber, French Martyn A, and Price Patricia

Subjects
Tuberculosis, HIV, IRIS, Meningitis, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Tuberculosis (TB) is the most common co infection in HIV-infected persons in India, requiring concomitant administration of anti TB and antiretroviral therapies. Paradoxical worsening of tuberculosis after anti-retroviral therapy (ART) initiation is frequently seen. Objective To study the frequency, clinical presentation and outcome of paradoxical tuberculosis associated immune reconstitution inflammatory syndrome (TB-IRIS) in HIV infected patients in a TB hospital in North India. Design A retrospective chart review of HIV-infected TB patients on anti-tubercular treatment (ATT) at time of ART initiation over a 3 year period. Medical records were reviewed for clinical manifestations and outcome in patients who developed TB-IRIS. Results 514 HIV-infected patients were enrolled between January 2006 and December 2008. Thirteen (12.6%) of 103 patients who had received ART and ATT simultaneously developed paradoxical TB-IRIS. Clinical presentations of paradoxical TB-IRIS included new lymphadenopathy (n = 3), increase in size of existing lymphadenopathy (n = 3), worsening of existing pulmonary lesions (n = 2), appearance of new pleural effusion (n = 1) and prolonged high grade fever (n = 2). Four patients developed new tubercular meningitis as manifestation of TB-IRIS. Our cases developed TB-IRIS a median of 15 days after starting ART (IQR 15–36). TB-IRIS patients were older (> 35 years) than those with no IRIS (P = 0.03), but were not distinguishable by CD4 T-cell count, duration of ATT before ART or the outcome of TB treatment. Eight (62%) patients had a complete recovery while 5 (38%) patients with TB-IRIS died, of which majority (n = 3) had meningitis. Conclusions Paradoxical TB-IRIS is a frequent problem during concomitant ATT and ART in HIV-TB co infected patients in north India. Meningitis is a potentially life threatening manifestation of TB-IRIS. more...

Published
2012
Full Text
View/download PDF

2. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

treatment–2017, The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB, Ahmad, Nafees, Ahuja, Shama D, Akkerman, Onno W, Alffenaar, Jan-Willem C, Anderson, Laura F, Baghaei, Parvaneh, Bang, Didi, Barry, Pennan M, Bastos, Mayara L, Behera, Digamber, Benedetti, Andrea, Bisson, Gregory P, Boeree, Martin J, Bonnet, Maryline, Brode, Sarah K, Brust, James CM, Cai, Ying, Caumes, Eric, Cegielski, J Peter, Centis, Rosella, Chan, Pei-Chun, Chan, Edward D, Chang, Kwok-Chiu, Charles, Macarthur, Cirule, Andra, Dalcolmo, Margareth Pretti, D'Ambrosio, Lia, de Vries, Gerard, Dheda, Keertan, Esmail, Aliasgar, Flood, Jennifer, Fox, Gregory J, Fréchet-Jachym, Mathilde, Fregona, Geisa, Gayoso, Regina, Gegia, Medea, Gler, Maria Tarcela, Gu, Sue, Guglielmetti, Lorenzo, Holtz, Timothy H, Hughes, Jennifer, Isaakidis, Petros, Jarlsberg, Leah, Kempker, Russell R, Keshavjee, Salmaan, Khan, Faiz Ahmad, Kipiani, Maia, Koenig, Serena P, Koh, Won-Jung, Kritski, Afranio, Kuksa, Liga, Kvasnovsky, Charlotte L, Kwak, Nakwon, Lan, Zhiyi, Lange, Christoph, Laniado-Laborín, Rafael, Lee, Myungsun, Leimane, Vaira, Leung, Chi-Chiu, Leung, Eric Chung-Ching, Li, Pei Zhi, Lowenthal, Phil, Maciel, Ethel L, Marks, Suzanne M, Mase, Sundari, Mbuagbaw, Lawrence, Migliori, Giovanni B, Milanov, Vladimir, Miller, Ann C, Mitnick, Carole D, Modongo, Chawangwa, Mohr, Erika, Monedero, Ignacio, Nahid, Payam, Ndjeka, Norbert, O'Donnell, Max R, Padayatchi, Nesri, Palmero, Domingo, Pape, Jean William, Podewils, Laura J, Reynolds, Ian, Riekstina, Vija, Robert, Jérôme, Rodriguez, Maria, Seaworth, Barbara, Seung, Kwonjune J, Schnippel, Kathryn, Shim, Tae Sun, Singla, Rupak, Smith, Sarah E, Sotgiu, Giovanni, Sukhbaatar, Ganzaya, Tabarsi, Payam, Tiberi, Simon, Trajman, Anete, Trieu, Lisa, Udwadia, Zarir F, van der Werf, Tjip S, and Veziris, Nicolas more...

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Tuberculosis, Lung, Antimicrobial Resistance, Prevention, Clinical Trials and Supportive Activities, Rare Diseases, Orphan Drug, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Amikacin, Antitubercular Agents, Capreomycin, Carbapenems, Clofazimine, Diarylquinolines, Drug Therapy, Combination, Fluoroquinolones, Humans, Kanamycin, Levofloxacin, Linezolid, Moxifloxacin, Recurrence, Treatment Failure, Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTreatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, and the optimal number and duration of treatment with those drugs in patients with multidrug-resistant tuberculosis.MethodsIn this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane Library to identify potentially eligible observational and experimental studies published between Jan 1, 2009, and April 30, 2016. We also searched reference lists from all systematic reviews of treatment of multidrug-resistant tuberculosis published since 2009. To be eligible, studies had to report original results, with end of treatment outcomes (treatment completion [success], failure, or relapse) in cohorts of at least 25 adults (aged >18 years). We used anonymised individual patient data from eligible studies, provided by study investigators, regarding clinical characteristics, treatment, and outcomes. Using propensity score-matched generalised mixed effects logistic, or linear regression, we calculated adjusted odds ratios and adjusted risk differences for success or death during treatment, for specific drugs currently used to treat multidrug-resistant tuberculosis, as well as the number of drugs used and treatment duration.FindingsOf 12 030 patients from 25 countries in 50 studies, 7346 (61%) had treatment success, 1017 (8%) had failure or relapse, and 1729 (14%) died. Compared with failure or relapse, treatment success was positively associated with the use of linezolid (adjusted risk difference 0·15, 95% CI 0·11 to 0·18), levofloxacin (0·15, 0·13 to 0·18), carbapenems (0·14, 0·06 to 0·21), moxifloxacin (0·11, 0·08 to 0·14), bedaquiline (0·10, 0·05 to 0·14), and clofazimine (0·06, 0·01 to 0·10). There was a significant association between reduced mortality and use of linezolid (-0·20, -0·23 to -0·16), levofloxacin (-0·06, -0·09 to -0·04), moxifloxacin (-0·07, -0·10 to -0·04), or bedaquiline (-0·14, -0·19 to -0·10). Compared with regimens without any injectable drug, amikacin provided modest benefits, but kanamycin and capreomycin were associated with worse outcomes. The remaining drugs were associated with slight or no improvements in outcomes. Treatment outcomes were significantly worse for most drugs if they were used despite in-vitro resistance. The optimal number of effective drugs seemed to be five in the initial phase, and four in the continuation phase. In these adjusted analyses, heterogeneity, based on a simulated I2 method, was high for approximately half the estimates for specific drugs, although relatively low for number of drugs and durations analyses.InterpretationAlthough inferences are limited by the observational nature of these data, treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis. These findings emphasise the need for trials to ascertain the optimal combination and duration of these drugs for treatment of this condition.FundingAmerican Thoracic Society, Canadian Institutes of Health Research, US Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America. more...

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results

3. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis—Report 2: Guidelines for Initiating Antitubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Retinal Vasculitis

Author

Agrawal, Rupesh, Testi, Ilaria, Bodaghi, Baharam, Barisani-Asenbauer, Talin, McCluskey, Peter, Agarwal, Aniruddha, Kempen, John H., Gupta, Amod, Smith, Justine R., Yuen, Yew Sen, Mahajan, Sarakshi, Agarwal, Mamta, Agarwal, Manisha, Aggarwal, Ashutosh, Aggarwal, Kanika, Agrawal, Mukesh, Al-Dhibi, Hassan, Androudi, Sofia, Asyari, Fatma, Balasundaram, Manohar Babu, Murthy, Kalpana Babu, Baglivo, Edoardo, Banker, Alay, Bansal, Reema, Basu, Soumyava, Behera, Digamber, Biswas, Jyotirmay, Carreño, Ester, Caspers, Laure, Chee, Soon Phaik, Chhabra, Romi, Cimino, Luca, Concha del Rio, Luz Elena, Cunningham, Emmett T., Land Curi, Andrè Luiz, Das, Dipankar, Davis, Janet, DeSmet, Marc, Denisova, Ekaterina, Denniston, Alastair K., Errera, Marie-Hélène, Fonollosa, Alejandro, George, Amala, Goldstein, Debra A., Crosier, Yan Guex, Gunasekeran, Dinesh Visva, Gurbaxani, Avinash, Invernizzi, Alessandro, Isa, Hazlita M., Islam, Shah M.d., Jones, Nicholas, Katoch, Deeksha, Khairallah, Moncef, Khosla, Amit, Kramer, Michal, Kumar, Amitabh, Kumar, Atul, La Distia Nora, Rina, Lee, Richard, Lowder, Careen, Luthra, Saurabh, Mahendradas, Padmamalini, Makhoul, Dorine, Mazumdar, Shahana, Mehta, Salil, Miserocchi, Elisabetta, Mochizuki, Manabu, Mohamed, Oli S., Muccioli, Cristina, Munk, Marion R., Murthy, Somasheila, Narain, Shishir, Nascimento, Heloisa, Neri, Piergiorgio, Nguyen, Myhanh, Okada, Annabelle A., Ozdal, Pinar, Palestine, Alan, Pichi, Francesco, Raje, Dhananjay, Rathinam, S.R., Rousselot, Andres, Schlaen, Ariel, Sehgal, Shobha, Nida Sen, H., Sharma, Aman, Sharma, Kusum, Shoughy, Samir S., Singh, Nirbhai, Singh, Ramandeep, Soheilian, Masoud, Sridharan, Sudharshan, Thorne, Jennifer E., Tappeiner, Christoph, Teoh, Stephen, Tognon, Maria Sofia, Tugal-Tutkun, Ilknur, Tyagi, Mudit, Uy, Harvey, Vasconcelos Santos, Daniel Vitor, Valentincic, Natasa Vidovic, Westcott, Mark, Yanai, Ryoji, Alvarez, Bety Yanez, Zahedur, Rahman, Zierhut, Manfred, Xian, Zheng, Kon, Onn Min, Nguyen, Quan Dong, Pavesio, Carlos, Gupta, Vishali, and de Smet, Marc D. more...

Published
2021
Full Text
View/download PDF

4. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis—Report 1: Guidelines for Initiating Antitubercular Therapy in Tubercular Choroiditis

Author

Agarwal, Mamta, Agarwal, Manisha, Aggarwal, Ashutosh, Aggarwal, Kanika, Agrawal, Mukesh, Al-Dhibi, Hassan, Androudi, Sofia, Asyari, Fatma, Balasundaram, Manohar Babu, Murthy, Kalpana Babu, Baglivo, Edoardo, Banker, Alay, Bansal, Reema, Basu, Soumyava, Behera, Digamber, Biswas, Jyotirmay, Bodaghi, Bahram, Carreño, Ester, Caspers, Laure, Chee, Soon Phaik, Chhabra, Romi, Cimino, Luca, Concha del Rio, Luz Elena, Cunningham, Emmett T., Land Curi, Andrè Luiz, Das, Dipankar, Davis, Janet, DeSmet, Marc, Denisova, Ekaterina, Denniston, Alastair K., Errera, Marie-Hélène, Fonollosa, Alejandro, George, Amala, Goldstein, Debra A., Crosier, Yan Guex, Gunasekeran, Dinesh Visva, Gurbaxani, Avinash, Invernizzi, Alessandro, Isa, Hazlita M., Islam, Shah Md., Jones, Nicholas, Katoch, Deeksha, Khairallah, Moncef, Khosla, Amit, Kramer, Michal, Kumar, Amitabh, Kumar, Atul, La Distia Nora, Rina, Lee, Richard, Lowder, Careen, Luthra, Saurabh, Mahendradas, Padmamalini, Makhoul, Dorine, Mazumdar, Shahana, McCluskey, Peter, Mehta, Salil, Miserocchi, Elisabetta, Mochizuki, Manabu, Mohamed, Oli S., Muccioli, Cristina, Munk, Marion R., Murthy, Somasheila, Narain, Shishir, Nascimento, Heloisa, Neri, Piergiorgio, Nguyen, Myhanh, Okada, Annabelle A., Ozdal, Pinar, Palestine, Alan, Pichi, Francesco, Raje, Dhananjay, Rathinam, S.R., Rousselot, Andres, Schlaen, Ariel, Sehgal, Shobha, Sen, H. Nida, Sharma, Aman, Sharma, Kusum, Shoughy, Samir S., Singh, Nirbhai, Singh, Ramandeep, Soheilian, Masoud, Sridharan, Sudharshan, Thorne, Jennifer E., Tappeiner, Christoph, Teoh, Stephen, Tognon, Maria Sofia, Tugal-Tutkun, Ilknur, Tyagi, Mudit, Uy, Harvey, Vasconcelos Santos, Daniel Vitor, Valentincic, Natasa Vidovic, Westcott, Mark, Yanai, Ryoji, Alvarez, Bety Yanez, Zahedur, Rahman, Zierhut, Manfred, Agrawal, Rupesh, Testi, Ilaria, Mahajan, Sarakshi, Yuen, Yew Sen, Agarwal, Aniruddha, Kon, Onn Min, Barisani-Asenbauer, Talin, Kempen, John H., Gupta, Amod, Jabs, Douglas A., Smith, Justine R., Nguyen, Quan Dong, Pavesio, Carlos, and Gupta, Vishali more...

Published
2021
Full Text
View/download PDF

6. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

Ahmad, Nafees, Ahuja, Shama D, Akkerman, Onno W, Alffenaar, Jan-Willem C, Anderson, Laura F, Baghaei, Parvaneh, Bang, Didi, Barry, Pennan M, Bastos, Mayara L, Behera, Digamber, Benedetti, Andrea, Bisson, Gregory P, Boeree, Martin J, Bonnet, Maryline, Brode, Sarah K, Brust, James C M, Cai, Ying, Caumes, Eric, Cegielski, J Peter, Centis, Rosella, Chan, Pei-Chun, Chan, Edward D, Chang, Kwok-Chiu, Charles, Macarthur, Cirule, Andra, Dalcolmo, Margareth Pretti, D'Ambrosio, Lia, de Vries, Gerard, Dheda, Keertan, Esmail, Aliasgar, Flood, Jennifer, Fox, Gregory J, Fréchet-Jachym, Mathilde, Fregona, Geisa, Gayoso, Regina, Gegia, Medea, Gler, Maria Tarcela, Gu, Sue, Guglielmetti, Lorenzo, Holtz, Timothy H, Hughes, Jennifer, Isaakidis, Petros, Jarlsberg, Leah, Kempker, Russell R, Keshavjee, Salmaan, Khan, Faiz Ahmad, Kipiani, Maia, Koenig, Serena P, Koh, Won-Jung, Kritski, Afranio, Kuksa, Liga, Kvasnovsky, Charlotte L, Kwak, Nakwon, Lan, Zhiyi, Lange, Christoph, Laniado-Laborín, Rafael, Lee, Myungsun, Leimane, Vaira, Leung, Chi-Chiu, Leung, Eric Chung-Ching, Li, Pei Zhi, Lowenthal, Phil, Maciel, Ethel L, Marks, Suzanne M, Mase, Sundari, Mbuagbaw, Lawrence, Migliori, Giovanni B, Milanov, Vladimir, Miller, Ann C, Mitnick, Carole D, Modongo, Chawangwa, Mohr, Erika, Monedero, Ignacio, Nahid, Payam, Ndjeka, Norbert, O'Donnell, Max R, Padayatchi, Nesri, Palmero, Domingo, Pape, Jean William, Podewils, Laura J, Reynolds, Ian, Riekstina, Vija, Robert, Jérôme, Rodriguez, Maria, Seaworth, Barbara, Seung, Kwonjune J, Schnippel, Kathryn, Shim, Tae Sun, Singla, Rupak, Smith, Sarah E, Sotgiu, Giovanni, Sukhbaatar, Ganzaya, Tabarsi, Payam, Tiberi, Simon, Trajman, Anete, Trieu, Lisa, Udwadia, Zarir F, van der Werf, Tjip S, Veziris, Nicolas, Viiklepp, Piret, Vilbrun, Stalz Charles, Walsh, Kathleen, Westenhouse, Janice, Yew, Wing-Wai, Yim, Jae-Joon, Zetola, Nicola M, Zignol, Matteo, and Menzies, Dick more...

Published
2018
Full Text
View/download PDF

10. Lung Cancer

Author

Behera, Digamber, Maturu, V. Nagarjuna, Droz, Jean-Pierre, editor, Carme, Bernard, editor, Couppié, Pierre, editor, Nacher, Mathieu, editor, and Thiéblemont, Catherine, editor

Published
2015
Full Text
View/download PDF

18. Single ascending dose safety, tolerability, and pharmacokinetic study of econazole in healthy volunteers

Author

Khera, Himanshi, primary, Pandey, Avaneesh Kumar, additional, Shafiq, Nusrat, additional, Khuller, G.K., additional, Kondel Bhandari, Ritika, additional, Panditrao, Aditi, additional, Gamad, Nanda, additional, Rohilla, Rachna, additional, Bhattacharjee, Samiksha, additional, Murali, Naveen, additional, cvn, Harish, additional, Belavagi, Devraj, additional, Mothsara, Chakrant, additional, Singh, Manjula, additional, Sharma, Navneet, additional, Behera, Digamber, additional, and Malhotra, Samir, additional more...

Published
2022
Full Text
View/download PDF

21. Indian Guidelines for diagnosis of respiratory allergy.

Author

Kumar, Raj, Gaur, Shailendra, Agarwal, Mahendra, Menon, Balakrishnan, Goel, Nitin, Mrigpuri, Parul, Spalgais, Sonam, Priya, Anshu, Kumar, Kapil, Meena, Rahul, Sankararaman, N, Verma, Arvind, Gupta, Vatsal, Sonal, Prakash, Anupam, Safwan, M, Behera, Digamber, Singh, Anand, Arora, Naveen, and Prasad, Rajendra more...

Subjects
ATOPY, MILK allergy, RESPIRATORY allergy, FOOD allergy, MEDICAL personnel, ALLERGENS, ALLERGIES
Abstract

In the same review, the RR of early-onset asthma associated with a maternal history of asthma was more (3.9 versus 3.3) compared to that of paternal asthma.[[153]] Children with a family history of asthma are suggested to have a more severe course.[[155]],[[156]] Although the association of adult-onset asthma with family history is weak than that of childhood-onset asthma, however, it is still a significant risk factor for adult-onset asthma. A family history of asthma is seen less frequently than those with early-onset asthma.[[111]] This phenotype of asthma is relatively steroid-resistant but highly responsive to biologic therapies targeting T2 pathways.[[112]],[[113]],[[114]],[[115]] Obesity-related asthma Obesity-related asthma is not a well-understood phenotype, and it is unclear whether it is comorbidity common in asthma that confers greater likelihood of breathing pattern disorder or it promotes a pro-inflammatory state that results in asthma.[[116]],[[117]],[[118]],[[119]] Higher body mass index (BMI) is associated with increased levels of inflammatory markers, such as, tumour necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), and leptins and fewer eosinophils, fractional exhaled nitric oxide (FeNO) and corticosteroid responsiveness.[[118]],[[119]] Clinically, this phenotype comprises of a group of older non-allergic, obese females who have significant symptoms but minimal health-care utilization.[[103]],[[104]] Neutrophilic asthma Neutrophilic asthma does not have a widely accepted definition, and the consensus about the characterization of this entity is also lacking. [Extracted from the article] more...

Published
2023
Full Text
View/download PDF

22. COVID-19 pandemic alert: time to focus on lung health-Beijing call to action for lung health promotion

Author

Tuyet Lan Le Thin, Sooronbaev Talant, Taborda-Barata Luis, Conceicao Claudia, Mohammad Yousser, Valiuis Arunas, Arzu Yorgancioglu, El Sony Asma, Cherian Varghese, M. Gaga, Harding Letitia, Teresa To, Halpin David, Bousquet Jean, Cruz Alvaro, Maghlakelidze Tamaz, Nunes Elizabete, Asthma Cen, Bennour Kazi, Williams Sian, Pigearias Bernard, Camargos Paolo, Wang Chen, Diaz Sandra Gonzales, Viegi Giovanni, Gaga Mina, Yorgancioglu Arzu, Giuseppe Troisi, Erhola Marina, Stelmach Rafael, Masjedi Muhammed Reza, Boulet Louis Philippe, Behera Digamber, Talant Sooranbaev, and Asher Innes more...

Subjects
Pulmonary and Respiratory Medicine, Focus (computing), Coronavirus disease 2019 (COVID-19), business.industry, media_common.quotation_subject, Editorial of GARD Section, Call to action, Promotion (rank), Beijing, Nursing, Lung health, Pandemic, Medicine, business, media_common
Published
2020

27. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis—Report 1

Author

Agrawal, Rupesh, primary, Testi, Ilaria, additional, Mahajan, Sarakshi, additional, Yuen, Yew Sen, additional, Agarwal, Aniruddha, additional, Kon, Onn Min, additional, Barisani-Asenbauer, Talin, additional, Kempen, John H., additional, Gupta, Amod, additional, Jabs, Douglas A., additional, Smith, Justine R., additional, Nguyen, Quan Dong, additional, Pavesio, Carlos, additional, Gupta, Vishali, additional, Agarwal, Mamta, additional, Agarwal, Manisha, additional, Aggarwal, Ashutosh, additional, Aggarwal, Kanika, additional, Agrawal, Mukesh, additional, Al-Dhibi, Hassan, additional, Androudi, Sofia, additional, Asyari, Fatma, additional, Balasundaram, Manohar Babu, additional, Murthy, Kalpana Babu, additional, Baglivo, Edoardo, additional, Banker, Alay, additional, Bansal, Reema, additional, Basu, Soumyava, additional, Behera, Digamber, additional, Biswas, Jyotirmay, additional, Bodaghi, Bahram, additional, Carreño, Ester, additional, Caspers, Laure, additional, Chee, Soon Phaik, additional, Chhabra, Romi, additional, Cimino, Luca, additional, Concha del Rio, Luz Elena, additional, Cunningham, Emmett T., additional, Land Curi, Andrè Luiz, additional, Das, Dipankar, additional, Davis, Janet, additional, DeSmet, Marc, additional, Denisova, Ekaterina, additional, Denniston, Alastair K., additional, Errera, Marie-Hélène, additional, Fonollosa, Alejandro, additional, George, Amala, additional, Goldstein, Debra A., additional, Crosier, Yan Guex, additional, Gunasekeran, Dinesh Visva, additional, Gurbaxani, Avinash, additional, Invernizzi, Alessandro, additional, Isa, Hazlita M., additional, Islam, Shah Md., additional, Jones, Nicholas, additional, Katoch, Deeksha, additional, Khairallah, Moncef, additional, Khosla, Amit, additional, Kramer, Michal, additional, Kumar, Amitabh, additional, Kumar, Atul, additional, La Distia Nora, Rina, additional, Lee, Richard, additional, Lowder, Careen, additional, Luthra, Saurabh, additional, Mahendradas, Padmamalini, additional, Makhoul, Dorine, additional, Mazumdar, Shahana, additional, McCluskey, Peter, additional, Mehta, Salil, additional, Miserocchi, Elisabetta, additional, Mochizuki, Manabu, additional, Mohamed, Oli S., additional, Muccioli, Cristina, additional, Munk, Marion R., additional, Murthy, Somasheila, additional, Narain, Shishir, additional, Nascimento, Heloisa, additional, Neri, Piergiorgio, additional, Nguyen, Myhanh, additional, Okada, Annabelle A., additional, Ozdal, Pinar, additional, Palestine, Alan, additional, Pichi, Francesco, additional, Raje, Dhananjay, additional, Rathinam, S.R., additional, Rousselot, Andres, additional, Schlaen, Ariel, additional, Sehgal, Shobha, additional, Sen, H. Nida, additional, Sharma, Aman, additional, Sharma, Kusum, additional, Shoughy, Samir S., additional, Singh, Nirbhai, additional, Singh, Ramandeep, additional, Soheilian, Masoud, additional, Sridharan, Sudharshan, additional, Thorne, Jennifer E., additional, Tappeiner, Christoph, additional, Teoh, Stephen, additional, Tognon, Maria Sofia, additional, Tugal-Tutkun, Ilknur, additional, Tyagi, Mudit, additional, Uy, Harvey, additional, Vasconcelos Santos, Daniel Vitor, additional, Valentincic, Natasa Vidovic, additional, Westcott, Mark, additional, Yanai, Ryoji, additional, Alvarez, Bety Yanez, additional, Zahedur, Rahman, additional, and Zierhut, Manfred, additional more...

Published
2021
Full Text
View/download PDF

28. The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings

Author

Agrawal, Rupesh, primary, Testi, Ilaria, additional, Mahajan, Sarakshi, additional, Yuen, Yew Sen, additional, Agarwal, Aniruddha, additional, Rousselot, Andres, additional, Raje, Dhananjay, additional, Gunasekeran, Dinesh Visva, additional, Kon, Onn Min, additional, Barisani-Asenbauer, Talin, additional, Kempen, John H., additional, Gupta, Amod, additional, Jabs, Douglas A., additional, Smith, Justine R., additional, Bodaghi, Bahram, additional, Zierhut, Manfred, additional, DeSmet, Marc, additional, Cluskey, Peter Mc, additional, Agarwal, Mamta, additional, Agarwal, Manisha, additional, Aggarwal, Kanika, additional, Agrawal, Mukesh, additional, Al-Dhibi, Hassan, additional, Androudi, Sofia, additional, Asyari, Fatma, additional, Balasundaram, Manohar Babu, additional, Murthy, Kalpana Babu, additional, Baglivo, Edoardo, additional, Banker, Alay, additional, Bansal, Reema, additional, Basu, Soumyava, additional, Behera, Digamber, additional, Biswas, Jyotirmay, additional, Carreño, Ester, additional, Caspers, Laure, additional, Chee, Soon Phaik, additional, Chhabra, Romi, additional, Cimino, Luca, additional, del Rio, Luz Elena Concha, additional, Cunningham, Emmett T., additional, Curi, Andrè Luiz Land, additional, Das, Dipankar, additional, Denisova, Ekaterina, additional, Denniston, Alastair K, additional, Errera, Marie-Hélène, additional, Fonollosa, Alejandro, additional, George, Amala, additional, Goldstein, Debra A., additional, Crosier, Yan Guex, additional, Gurbaxani, Avinash, additional, Invernizzi, Alessandro, additional, Isa, Hazlita M., additional, Md. Islam, Shah, additional, Jones, Nicholas, additional, Katoch, Deeksha, additional, Khairallah, Moncef, additional, Khosla, Amit, additional, Kramer, Michal, additional, Kumar, Amitabh, additional, Kumar, Atul, additional, Nora, Rina La Distia, additional, Lee, Richard, additional, Lowder, Careen, additional, Luthra, Saurabh, additional, Mahendradas, Padmamalini, additional, Makhoul, Dorine, additional, Mazumdar, Shahana, additional, Mehta, Salil, additional, Miserocchi, Elisabetta, additional, Mochizuki, Manabu, additional, Mohamed, Oli S., additional, Muccioli, Cristina, additional, Munk, Marion R, additional, Murthy, Somasheila, additional, Narain, Shishir, additional, Nascimento, Heloisa, additional, Neri, Piergiorgio, additional, Nguyen, Myhanh, additional, Okada, Annabelle A., additional, Ozdal, Pinar, additional, Palestine, Alan, additional, Pichi, Francesco, additional, Rathinam, S.R, additional, Schlaen, Ariel, additional, Sehgal, Shobha, additional, Sen, H Nida, additional, Sharma, Aman, additional, Sharma, Kusum, additional, Shoughy, Samir S., additional, Singh, Nirbhai, additional, Singh, Ramandeep, additional, Soheilian, Masoud, additional, Sridharan, Sudharshan, additional, Thorne, Jennifer E., additional, Tappeiner, Christoph, additional, Teoh, Stephen, additional, Tognon, Maria Sofia, additional, Tugal-Tutkun, Ilknur, additional, Tyagi, Mudit, additional, Uy, Harvey, additional, Santos, Daniel Vitor Vasconcelos, additional, Valentincic, Natasa Vidovic, additional, Westcott, Mark, additional, Yanai, Ryoji, additional, Alvarez, Bety Yanez, additional, Zahedur, Rahman, additional, Nguyen, Quan Dong, additional, Pavesio, Carlos, additional, and Gupta, Vishali, additional more...

Published
2020
Full Text
View/download PDF

30. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad, Nafees, Ahuja, Shama D, Akkerman, Onno W, Alffenaar, Jan-Willem C, Anderson, Laura F, Baghaei, Parvaneh, Bang, Didi, Barry, Pennan M, Bastos, Mayara L, Behera, Digamber, Benedetti, Andrea, Bisson, Gregory P, Boeree, Martin J, Bonnet, Maryline, Brode, Sarah K, Brust, James CM, Cai, Ying, Caumes, Eric, Cegielski, J Peter, Centis, Rosella, Chan, Pei-Chun, Chan, Edward D, Chang, Kwok-Chiu, Charles, Macarthur, Cirule, Andra, Dalcolmo, Margareth Pretti, D'Ambrosio, Lia, de Vries, Gerard, Dheda, Keertan, Esmail, Aliasgar, Flood, Jennifer, Fox, Gregory J, Fréchet-Jachym, Mathilde, Fregona, Geisa, Gayoso, Regina, Gegia, Medea, Gler, Maria Tarcela, Gu, Sue, Guglielmetti, Lorenzo, Holtz, Timothy H, Hughes, Jennifer, Isaakidis, Petros, Jarlsberg, Leah, Kempker, Russell R, Keshavjee, Salmaan, Khan, Faiz Ahmad, Kipiani, Maia, Koenig, Serena P, Koh, Won-Jung, Kritski, Afranio, Kuksa, Liga, Kvasnovsky, Charlotte L, Kwak, Nakwon, Lan, Zhiyi, Lange, Christoph, Laniado-Laborín, Rafael, Lee, Myungsun, Leimane, Vaira, Leung, Chi-Chiu, Leung, Eric Chung-Ching, Li, Pei Zhi, Lowenthal, Phil, Maciel, Ethel L, Marks, Suzanne M, Mase, Sundari, Mbuagbaw, Lawrence, Migliori, Giovanni B, Milanov, Vladimir, Miller, Ann C, Mitnick, Carole D, Modongo, Chawangwa, Mohr, Erika, Monedero, Ignacio, Nahid, Payam, Ndjeka, Norbert, O'Donnell, Max R, Padayatchi, Nesri, Palmero, Domingo, Pape, Jean William, Podewils, Laura J, Reynolds, Ian, Riekstina, Vija, Robert, Jérôme, Rodriguez, Maria, Seaworth, Barbara, Seung, Kwonjune J, Schnippel, Kathryn, Shim, Tae Sun, Singla, Rupak, Smith, Sarah E, Sotgiu, Giovanni, Sukhbaatar, Ganzaya, Tabarsi, Payam, Tiberi, Simon, Trajman, Anete, Trieu, Lisa, Udwadia, Zarir F, van der Werf, Tjip S, and Veziris, Nicolas more...

Subjects
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Moxifloxacin, Clinical Trials and Supportive Activities, Antitubercular Agents, Levofloxacin, Clofazimine, Medical and Health Sciences, Rare Diseases, Drug Therapy, Recurrence, Kanamycin, Clinical Research, General & Internal Medicine, Humans, Tuberculosis, Treatment Failure, Capreomycin, Diarylquinolines, Amikacin, Lung, Prevention, Linezolid, Evaluation of treatments and therapeutic interventions, Pulmonary, Multidrug-Resistant, Orphan Drug, Good Health and Well Being, Carbapenems, 6.1 Pharmaceuticals, Combination, Antimicrobial Resistance, Infection, Fluoroquinolones
Abstract

BackgroundTreatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, and the optimal number and duration of treatment with those drugs in patients with multidrug-resistant tuberculosis.MethodsIn this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane Library to identify potentially eligible observational and experimental studies published between Jan 1, 2009, and April 30, 2016. We also searched reference lists from all systematic reviews of treatment of multidrug-resistant tuberculosis published since 2009. To be eligible, studies had to report original results, with end of treatment outcomes (treatment completion [success], failure, or relapse) in cohorts of at least 25 adults (aged >18 years). We used anonymised individual patient data from eligible studies, provided by study investigators, regarding clinical characteristics, treatment, and outcomes. Using propensity score-matched generalised mixed effects logistic, or linear regression, we calculated adjusted odds ratios and adjusted risk differences for success or death during treatment, for specific drugs currently used to treat multidrug-resistant tuberculosis, as well as the number of drugs used and treatment duration.FindingsOf 12 030 patients from 25 countries in 50 studies, 7346 (61%) had treatment success, 1017 (8%) had failure or relapse, and 1729 (14%) died. Compared with failure or relapse, treatment success was positively associated with the use of linezolid (adjusted risk difference 0·15, 95% CI 0·11 to 0·18), levofloxacin (0·15, 0·13 to 0·18), carbapenems (0·14, 0·06 to 0·21), moxifloxacin (0·11, 0·08 to 0·14), bedaquiline (0·10, 0·05 to 0·14), and clofazimine (0·06, 0·01 to 0·10). There was a significant association between reduced mortality and use of linezolid (-0·20, -0·23 to -0·16), levofloxacin (-0·06, -0·09 to -0·04), moxifloxacin (-0·07, -0·10 to -0·04), or bedaquiline (-0·14, -0·19 to -0·10). Compared with regimens without any injectable drug, amikacin provided modest benefits, but kanamycin and capreomycin were associated with worse outcomes. The remaining drugs were associated with slight or no improvements in outcomes. Treatment outcomes were significantly worse for most drugs if they were used despite in-vitro resistance. The optimal number of effective drugs seemed to be five in the initial phase, and four in the continuation phase. In these adjusted analyses, heterogeneity, based on a simulated I2 method, was high for approximately half the estimates for specific drugs, although relatively low for number of drugs and durations analyses.InterpretationAlthough inferences are limited by the observational nature of these data, treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis. These findings emphasise the need for trials to ascertain the optimal combination and duration of these drugs for treatment of this condition.FundingAmerican Thoracic Society, Canadian Institutes of Health Research, US Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America. more...

Published
2018

41. Association study between genetic variations in Axin2 gene and lung cancer risk in North Indian population: A multiple interaction analysis.

Author

Bahl, Charu, Sharma, Siddharth, Singh, Navneet, and Behera, Digamber

Abstract

Wnt pathway has been implicated in the process of human carcinogenesis. Axis inhibition protein2 (Axin2), a major scaffold protein is an antagonist of Wnt pathway and is potent to act as a tumor suppressor gene in various human cancers. Therefore, the seven polymorphic sites of Axin2 gene were analyzed, in relation to lung cancer susceptibility in North Indians. A total of 608 subjects were genotyped using PCR-RFLP technique for each polymorphic site including 303 cases and 305 controls. Further association analysis was carried out using logistic regression approach to obtain adjusted odds ratio and statistical significance. MDR and CART analysis were applied to evaluate high order interactions between the SNP's. Three out of seven studied polymorphic sites showed a strong protective effect in subjects having mutant genotype for Axin2 148 C >T and heterozygous genotype for 1365 G > A and 1712 + 19 G > T towards lung cancer risk. The other important finding was the significant association of Axin2 148 C >T in SQCC patients having variant (TT) genotype. Axin2 1712 + 19 G >T showed a decreased risk for all the histological subtypes in patients with heterozygous (GT) genotype. MDR analysis predicted a best interaction model (Axin2 148, Axin2 2062 and Axin2 1712 +19) with maximum CVC (10/10) and minimum prediction error (0.38) along with significant permutation p-value. CART analysis gave a wide spectrum of interactive combinations which exhibited a major contribution in modulating lung cancer susceptibility. Axin2 148 and Axin2 1712 + 19 were found to play a major role in modulating lung cancer risk. [ABSTRACT FROM AUTHOR] more...

Published
2017
Full Text
View/download PDF

43. Development of a POC Test for TB Based on Multiple Immunodominant Epitopes of M. tuberculosis Specific Cell-Wall Proteins

Author

Gonzalez, Jesus M., primary, Francis, Bryan, additional, Burda, Sherri, additional, Hess, Kaitlyn, additional, Behera, Digamber, additional, Gupta, Dheeraj, additional, Agarwal, Ashutosh Nath, additional, Verma, Indu, additional, Verma, Ajoy, additional, Myneedu, Vithal Prasad, additional, Niedbala, Sam, additional, and Laal, Suman, additional more...

Published
2014
Full Text
View/download PDF

44. Impact of Introducing the Line Probe Assay on Time to Treatment Initiation of MDR-TB in Delhi, India

Author

Singla, Neeta, primary, Satyanarayana, Srinath, additional, Sachdeva, Kuldeep Singh, additional, Van den Bergh, Rafael, additional, Reid, Tony, additional, Tayler-Smith, Katherine, additional, Myneedu, V. P., additional, Ali, Engy, additional, Enarson, Donald A., additional, Behera, Digamber, additional, and Sarin, Rohit, additional more...

Published
2014
Full Text
View/download PDF

45. Identification of hot and cold spots in genome of Mycobacterium tuberculosis using Shewhart Control Charts.

Author

Das, Sarbashis, Duggal, Priyanka, Roy, Rahul, Myneedu, Vithal P, Behera, Digamber, Prasad, Hanumanthappa K, Bhattacharya, Alok, Das, Sarbashis, Duggal, Priyanka, Roy, Rahul, Myneedu, Vithal P, Behera, Digamber, Prasad, Hanumanthappa K, and Bhattacharya, Alok more...

Abstract

The organization of genomic sequences is dynamic and undergoes change during the process of evolution. Many of the variations arise spontaneously and the observed genomic changes can either be distributed uniformly throughout the genome or be preferentially localized to some regions (hot spots) compared to others. Conversely cold spots may tend to accumulate very few variations or none at all. In order to identify such regions statistically, we have developed a method based on Shewhart Control Chart. The method was used for identification of hot and cold spots of single-nucleotide variations (SNVs) in Mycobacterium tuberculosis genomes. The predictions have been validated by sequencing some of these regions derived from clinical isolates. This method can be used for analysis of other genome sequences particularly infectious microbes. more...

Published
2012
Full Text
View/download PDF

49. Direct Drug Susceptibility Testing of Mycobacterium tuberculosis for Rapid Detection of Multidrug Resistance Using the Bactec MGIT 960 System: a Multicenter Study

Author

Siddiqi, Salman, primary, Ahmed, Altaf, additional, Asif, Sunil, additional, Behera, Digamber, additional, Javaid, Mona, additional, Jani, Jasmine, additional, Jyoti, Arora, additional, Mahatre, Radhika, additional, Mahto, Dewanand, additional, Richter, Elvira, additional, Rodrigues, Camilla, additional, Visalakshi, Potharaju, additional, and Rüsch-Gerdes, Sabine, additional more...

Published
2012
Full Text
View/download PDF